Peptide Ratio SubmitPR·SUBMIT.SITE
℞ REFERENCE Find by condition
HomeDictionaryFind by ConditionCalculatorsHistoryNews & RegulatoryHow We RateAbout

Navigate

HomeDictionaryFind by ConditionCalculatorsHistoryNews & RegulatoryHow We RateAbout

Browse by family

MetabolicRepairGrowth hormoneNeuroLongevityImmuneMelanocortinCosmeticBone
Human trialsMetabolic IBI362, LY3305677

Mazdutide

An oxyntomodulin-based dual agonist approved in China, unapproved in the US.

Class
Dual GLP-1 / glucagon receptor agonist
Molar mass
~4,500 g/mol
Half-life
~5 days
Human PK
Published
Regulatory
Approved in China; not FDA-approved
Sport
Not prohibited

What it is claimed to help

These are the uses attached to Mazdutide in research, clinical practice, or marketing. Listing a claim is not endorsing it — tap any of them to see every other compound carrying the same claim.

What the human evidence actually is

Grade: Human trials

Randomised controlled human trials exist. Not necessarily approved, and not necessarily positive.

Multiple Chinese phase 3 trials (GLORY, DREAMS) reported meaningful weight and glycaemic benefit, leading to approval by China's NMPA in 2025. No FDA approval.

How it is supposed to work

Based on the natural hormone oxyntomodulin; agonises GLP-1 and glucagon receptors.

Safety

Class GI effects. Regulatory review outside China is incomplete.

Storage and handling

Lyophilised peptide is generally stored at 2–8 °C, or below −20 °C for long-term storage. Reconstituted in bacteriostatic water (0.9% benzyl alcohol) a solution is typically treated as usable for about 28 days refrigerated, versus roughly 24 hours for plain sterile water, which has no preservative. Add the water slowly down the vial wall and swirl — never shake, which shears peptide chains and foams the solution.

The arithmetic is the dangerous part

Whatever number a protocol or a prescriber gave you, converting it into syringe units is where a misplaced decimal becomes a tenfold error. Our calculators do that conversion and nothing else — they never invent a dose.

Open the calculators

Sources

  1. GLORY-1 phase 3, 2024
  2. China NMPA approval notice, 2025

Verified against primary sources on 27 August 2026. Regulatory status in this field changes several times a year. See How We Rate Evidence.

← Survodutide All compounds Setmelanotide →